SEC Info - Acceleron Pharma Inc. - ‘8-K’ for 4/5/21

SEC Info℠

Home

Help

Please Sign In

Acceleron Pharma Inc. – ‘8-K’ for 4/5/21

On: Monday, 4/5/21, at 7:22am ET · For: 4/5/21 · Accession #: 1280600-21-21 · File #: 1-36065

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/05/21  Acceleron Pharma Inc.             8-K:8,9     4/05/21   13:326K

Current Report — Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     29K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     24K 
 9: R1          Cover Page                                          HTML     48K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- xlrn-20210405_htm                   XML     21K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.CAL  XBRL Calculations -- xlrn-20210405_cal               XML      7K 
 5: EX-101.DEF  XBRL Definitions -- xlrn-20210405_def                XML     12K 
 6: EX-101.LAB  XBRL Labels -- xlrn-20210405_lab                     XML     73K 
 7: EX-101.PRE  XBRL Presentations -- xlrn-20210405_pre              XML     37K 
 3: EX-101.SCH  XBRL Schema -- xlrn-20210405                         XSD     11K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
13: ZIP         XBRL Zipped Folder -- 0001280600-21-000021-xbrl      Zip     18K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

xlrn-20210405

i 0001280600 i false00012806002021-04-052021-04-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

FORM i 8-K

___________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i April 5, 2021

___________________________

i ACCELERON PHARMA INC.

(Exact name of Registrant as specified in its charter)

i Delaware

i 001-36065

i 27-0072226

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

i 128 Sidney Street

i Cambridge,

i MA

i 02139

(Address of principal

executive offices)

(Zip Code)

Registrant’s telephone number, including area code: ( i 617) i 649-9200

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:


Title of each class	Ticker Symbol(s)	Name of each exchange on which registered
i Common Stock, $0.001 per share	i XLRN	i The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On April 5, 2021, Acceleron Pharma Inc. issued a press release titled "Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society (ATS) 2021 International Conference." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number						Description of Exhibit
99.1						Press release of Acceleron Pharma Inc. dated April 5, 2021
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ACCELERON PHARMA INC.


	By:	/s/ *Adam M. Veness, Esq.*
		Adam M. Veness, Esq.
		Senior Vice President, General Counsel and Secretary

Date: April 5, 2021

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	4/5/21	4
		List all Filings

↑Top

Filing Submission 0001280600-21-000021 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Acceleron Pharma Inc. – ‘8-K’ for 4/5/21

On: Monday, 4/5/21, at 7:22am ET · For: 4/5/21 · Accession #: 1280600-21-21 · File #: 1-36065

Previous ‘8-K’: ‘8-K’ on / for 2/25/21 · Next: ‘8-K’ on / for 4/29/21 · Latest: ‘8-K’ on 11/22/21 for 11/19/21

Current Report — Form 8-KFiling Table of Contents

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Current Report — Form 8-K
Filing Table of Contents